» Articles » PMID: 19343203

Anthrax Lethal Toxin Impairs IL-8 Expression in Epithelial Cells Through Inhibition of Histone H3 Modification

Overview
Journal PLoS Pathog
Specialty Microbiology
Date 2009 Apr 4
PMID 19343203
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Lethal toxin (LT) is a critical virulence factor of Bacillus anthracis, the etiological agent of anthrax, whose pulmonary form is fatal in the absence of treatment. Inflammatory response is a key process of host defense against invading pathogens. We report here that intranasal instillation of a B. anthracis strain bearing inactive LT stimulates cytokine production and polymorphonuclear (PMN) neutrophils recruitment in lungs. These responses are repressed by a prior instillation of an LT preparation. In contrast, instillation of a B. anthracis strain expressing active LT represses lung inflammation. The inhibitory effects of LT on cytokine production are also observed in vitro using mouse and human pulmonary epithelial cells. These effects are associated with an alteration of ERK and p38-MAPK phosphorylation, but not JNK phosphorylation. We demonstrate that although NF-kappaB is essential for IL-8 expression, LT downregulates this expression without interfering with NF-kappaB activation in epithelial cells. Histone modifications are known to induce chromatin remodelling, thereby enhancing NF-kappaB binding on promoters of a subset of genes involved in immune response. We show that LT selectively prevents histone H3 phosphorylation at Ser 10 and recruitment of the p65 subunit of NF-kappaB at the IL-8 and KC promoters. Our results suggest that B. anthracis represses the immune response, in part by altering chromatin accessibility of IL-8 promoter to NF-kappaB in epithelial cells. This epigenetic reprogramming, in addition to previously reported effects of LT, may represent an efficient strategy used by B. anthracis for invading the host.

Citing Articles

Future applications of host direct therapies for infectious disease treatment.

Thom R, DElia R Front Immunol. 2024; 15:1436557.

PMID: 39411713 PMC: 11473292. DOI: 10.3389/fimmu.2024.1436557.


, "la maladie du charbon", Toxins, and Institut Pasteur.

Goossens P Toxins (Basel). 2024; 16(2).

PMID: 38393144 PMC: 10891547. DOI: 10.3390/toxins16020066.


Epigenetic interaction of microbes with their mammalian hosts.

Rajeev R, Dwivedi A, Sinha A, Agarwaal V, Dev R, Kar A J Biosci. 2021; 46.

PMID: 34728591 PMC: 8550911.


Functional differences and similarities in activated peripheral blood mononuclear cells by lipopolysaccharide or phytohemagglutinin stimulation between human and cynomolgus monkeys.

Lin Z, Huang Y, Jiang H, Zhang D, Yang Y, Geng X Ann Transl Med. 2021; 9(3):257.

PMID: 33708884 PMC: 7940909. DOI: 10.21037/atm-20-4548.


Trained immunity and host-pathogen interactions.

Peignier A, Parker D Cell Microbiol. 2020; 22(12):e13261.

PMID: 32902895 PMC: 7655595. DOI: 10.1111/cmi.13261.


References
1.
Duesbery N, Webb C, Leppla S, Gordon V, Klimpel K, Copeland T . Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science. 1998; 280(5364):734-7. DOI: 10.1126/science.280.5364.734. View

2.
Mock M, Fouet A . Anthrax. Annu Rev Microbiol. 2001; 55:647-71. DOI: 10.1146/annurev.micro.55.1.647. View

3.
Russell B, Liu Q, Jenkins S, Tuvim M, Dickey B, Xu Y . In vivo demonstration and quantification of intracellular Bacillus anthracis in lung epithelial cells. Infect Immun. 2008; 76(9):3975-83. PMC: 2519418. DOI: 10.1128/IAI.00282-08. View

4.
Pickering A, Osorio M, Lee G, Grippe V, Bray M, Merkel T . Cytokine response to infection with Bacillus anthracis spores. Infect Immun. 2004; 72(11):6382-9. PMC: 523056. DOI: 10.1128/IAI.72.11.6382-6389.2004. View

5.
Raymond B, Leduc D, Ravaux L, Le Goffic R, Candela T, Raymondjean M . Edema toxin impairs anthracidal phospholipase A2 expression by alveolar macrophages. PLoS Pathog. 2007; 3(12):e187. PMC: 2134952. DOI: 10.1371/journal.ppat.0030187. View